Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases

Journal of Medicinal Chemistry

Volumn 50, Issue 10, 2007, Pages 2301-2309

  Ren, Jingshan ^a   Nichols, Charles E ^a   Chamberlain, Philip P ^a   Weaver, Kurt L ^b   Short, Steven A ^b   Chan, Joseph H ^b   Kleim, Jörg Peter ^c   Stammers, David K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE;

ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG STRUCTURE; WILD TYPE;

ANTI-HIV AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PROTEIN BINDING; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34248998744     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061117m     Document Type: Article

References (44)

1. De Clercq, E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 2001, 8 (13), 1543-1572.
2. Goff, S. P. Retroviral reverse transcriptase: Synthesis, structure, and function. J. Acquired Immune Defic. Syndr. 1990, 3, 817-831.
3. Di Marzo Veronese, F.; Copeland, T. D.; De Vico, A. L.; Rahman, R.; Oroszlan, S.; Gallo, R. C.; Sarngadharan, M. G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231, 1289-1291.
4. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
5. Jacobo-Molina, A.; Ding, J. P.; Nanni, R. G.; Clark, A. D. J.; Lu, X.; Tantillo, C.; Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320-6324.
6. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Structural Biology 1995, 2, 293-302.
7. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
8. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 1998, 282, 1669-1675.
9. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
10. Ren, J.; Diprose, J.; Warren, J.; Esnouf, R. M.; Bird, L. E.; Ikemizu, S.; Slater, M.; Milton, J.; Balzarini, J.; Stuart, D. I.; Stammers, D. K. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases: Structural and biochemical analyses. J. Biol. Chem. 2000, 275, 5633-5639.
11. Richman, D.; Shih, C.-K.; Lowy, I.; Rose, J.; Prodanovieh, P.; Goff, S.; Griffin, J. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11241-11245.
12. Moyle, G. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs 2001, 61, 19-26.
13. Sardana, V. V.; Emini, E. A.; Gotlib, L.; Graham, D. J.; Lineberger, D. W.; Long, W. J.; Wolfgang, J. A.; Condra, J. H. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J. Biol. Chem. 1992, 267, 17526-17530.
14. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumina, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; O'Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I.-W.; Schleif, W. A.; Sardana, V. V.; Long, W. J.; Byrnes, V. W.; Emini, E. A. L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
15. Fujiwara, T.; Sato, A.; el-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42, 1340-1345.
16. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
17. Balzarini, J.; De Clercq, E.; Carbonez, A.; Burt, V.; Kleim, J. P. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retroviruses 2000, 16, 517-528.
18. Arasteh, K.; Wood, R.; Muller, M.; Prince, W.; Cass, L.; Moore, K. H.; Dallow, N.; Jones, A.; Klein, A.; Burt, V.; Kleim, J. P. GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine. HIV Clin. Trials 2001, 2 (4), 307-16.
19. Moore, K. H.; Cass, L. M.; Dallow, N.; Hardman, T. C.; Jones, A.; Boyce, M.; Prince, W. T. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers. J. Clin. Pharmacol. 2001, 41 (10), 1098-105.
20. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Struct. Fold. Des. 2000, 8, 1089-1094.
21. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 2001, 312 (4), 795-805.
22. Ren, J.; Nichols, C. E.; Chamberlain, P. P.; Weaver, K. L.; Short, S. A.; Stammers, D. K. Crystal structures of HIV-1 reverse transcriptase mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 2004, 336, 569-578.
23. Ren, J.; Nichols, C. E.; Stamp, A.; Chamberlain, P. P.; Ferris, R.; Weaver, K. L.; Short, S. A.; Stammers, D. K. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J. 2006, 273 (16), 3850-3860.
24. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
25. Hsiou, Y.; Das, K.; Ding, J.; Clark, A. D.; Kleim, J.-P.; Rosner, M.; Winkler, I.; Riess, C.; Hughes, S. H.; Arnold, E. HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 1998, 284, 313-323.
26. Esnouf, R. M.; Ren, J.; Hopkins, A. L.; Ross, C. K.; Jones, E. Y.; Stammers, D. K.; Stuart, D. I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)-piperazine (BHAP) U-90152 explain resistance mutations for this non-nucleoside inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 3984-3989.
27. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
28. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 1995, 3, 915-926.
29. Ren, J.; Nichols, C. E.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D. I.; Stammers, D. K. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 RT involves extensive main chain hydrogen bonding. J. Biol. Chem. 2000, 275, 14316-14320.
30. Tanaka, H.; Baba, M.; Hayakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; Balzarini, J.; De Clercq, E. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6- substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 349-357.
31. Ren, J.; Esnouf, R. M.; Hopkins, A. L.; Warren, J.; Balzarini, J.; Stuart, D. I.; Stammers, D. K. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 1998, 37, 14394-14403.
32. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D. J.; Jessen, S.; Lu, X.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H. J.; Kroeger Koepke, R.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
33. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P. A.; Boyer, P. L.; Clark, P.; Smith, R. H.; Kroeger Smith, M. B.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with theTyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 1996, 264, 1085-1100.
34. Stammers, D. K.; Somers, D. O. N.; Ross, C. K.; Kirby, I.; Ray, P. H.; Wilson, J. E.; Norman, M.; Ren, J. S.; Esnouf, R. M.; Garman, E. F.; Jones, E. Y.; Stuart, D. I. Crystals of HIV-1 reverse transcriptase diffracting to 2.2Å resolution. J. Mol. Biol. 1994, 242, 586-588.
35. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1996, 276, 307-326.
36. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse, K. R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. 1998, D54, 905-921.
37. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47, 110-119.
38. Balzarini, J.; Pelemans, H.; Aquaro, S.; Perno, C. F.; Witvrouw, M.; Schols, D.; De Clercq, E.; Karlsson, A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 1996, 50, 394-401.
39. Buckheit, R. W.; Snow, M. J.; Fliakas-Boltz, V.; Kinjerski, T. L.; Russell, J. D.; Pallansch, L. A.; Brouwer, W. G.; Yang, S. S. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 1997, 41, 831-837.
40. Chan, J. H.; Hong, J. S.; Hunter, R. N., III; Orr, G. F.; Cowan, J. R.; Sherman, D. B.; Sparks, S. M.; Renter, B. E.; Andrews, C. W., III; Hazen, R. J.; St Clair, M.; Boone, L. R.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K.; Ott, R. J.; Ren, J.; Hopkins, A.; Stuart, D. I.; Stammers, D. K. 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 2001, 44 (12), 1866-1882.
41. Chan, J. Unpublished data.
42. Hazen, R. J.; Harvey, R. J.; St Clair, M. H.; Ferris, R. G.; Freeman, G. A.; Tidwell, J. H.; Schaller, L. T.; Cowan, J. R.; Short, S. A.; Romines, K. R.; Chan, J. H.; Boone, L. R. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob. Agents Chemother. 2005, 49 (11), 4465-4473.
43. Petropoulos, C. J.; Parkin, N. T.; Limoli, K. L.; Lie, Y. S.; Wrin, T.; Huang, W.; Tian, H.; Smith, D.; Winslow, G. A.; Capon, D. J.; Whitcomb, J. M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44 (4), 920-928.
44. Yang, S. S.; Pattabiraman, N.; Gussio, R.; Pallansch, L.; Buckheit, R. W.; Bader, J. P. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus. Leukemia 1997, 11, 89-92.